Jasper Therapeutics (JSPR) Competitors $4.46 -0.38 (-7.85%) Closing price 03/28/2025 04:00 PM EasternExtended Trading$4.55 +0.09 (+2.02%) As of 03/28/2025 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock JSPR vs. ATAI, TERN, PROK, ANNX, GOSS, CMPS, SEPN, CADL, DSGN, and AVIRShould you be buying Jasper Therapeutics stock or one of its competitors? The main competitors of Jasper Therapeutics include Atai Life Sciences (ATAI), Terns Pharmaceuticals (TERN), ProKidney (PROK), Annexon (ANNX), Gossamer Bio (GOSS), COMPASS Pathways (CMPS), Septerna (SEPN), Candel Therapeutics (CADL), Design Therapeutics (DSGN), and Atea Pharmaceuticals (AVIR). These companies are all part of the "pharmaceutical products" industry. Jasper Therapeutics vs. Atai Life Sciences Terns Pharmaceuticals ProKidney Annexon Gossamer Bio COMPASS Pathways Septerna Candel Therapeutics Design Therapeutics Atea Pharmaceuticals Jasper Therapeutics (NASDAQ:JSPR) and Atai Life Sciences (NASDAQ:ATAI) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their community ranking, media sentiment, risk, institutional ownership, valuation, profitability, dividends, earnings and analyst recommendations. Which has better earnings and valuation, JSPR or ATAI? Atai Life Sciences has higher revenue and earnings than Jasper Therapeutics. Atai Life Sciences is trading at a lower price-to-earnings ratio than Jasper Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioJasper TherapeuticsN/AN/A-$64.46M-$4.86-0.92Atai Life Sciences$308K946.46-$40.22M-$0.93-1.58 Do analysts recommend JSPR or ATAI? Jasper Therapeutics presently has a consensus price target of $62.50, suggesting a potential upside of 1,301.35%. Atai Life Sciences has a consensus price target of $9.00, suggesting a potential upside of 512.24%. Given Jasper Therapeutics' higher possible upside, analysts clearly believe Jasper Therapeutics is more favorable than Atai Life Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Jasper Therapeutics 0 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 3.00Atai Life Sciences 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media prefer JSPR or ATAI? In the previous week, Atai Life Sciences had 2 more articles in the media than Jasper Therapeutics. MarketBeat recorded 4 mentions for Atai Life Sciences and 2 mentions for Jasper Therapeutics. Jasper Therapeutics' average media sentiment score of 1.29 beat Atai Life Sciences' score of 0.63 indicating that Jasper Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Jasper Therapeutics Positive Atai Life Sciences Positive Is JSPR or ATAI more profitable? Atai Life Sciences' return on equity of -65.75% beat Jasper Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Jasper TherapeuticsN/A -67.64% -58.53% Atai Life Sciences N/A -65.75%-52.71% Do institutionals and insiders believe in JSPR or ATAI? 79.8% of Jasper Therapeutics shares are held by institutional investors. Comparatively, 28.4% of Atai Life Sciences shares are held by institutional investors. 2.7% of Jasper Therapeutics shares are held by company insiders. Comparatively, 31.2% of Atai Life Sciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Does the MarketBeat Community favor JSPR or ATAI? Atai Life Sciences received 288 more outperform votes than Jasper Therapeutics when rated by MarketBeat users. However, 90.20% of users gave Jasper Therapeutics an outperform vote while only 66.53% of users gave Atai Life Sciences an outperform vote. CompanyUnderperformOutperformJasper TherapeuticsOutperform Votes4690.20% Underperform Votes59.80%Atai Life SciencesOutperform Votes33466.53% Underperform Votes16833.47% Which has more risk and volatility, JSPR or ATAI? Jasper Therapeutics has a beta of 2.23, indicating that its share price is 123% more volatile than the S&P 500. Comparatively, Atai Life Sciences has a beta of 1.18, indicating that its share price is 18% more volatile than the S&P 500. SummaryAtai Life Sciences beats Jasper Therapeutics on 8 of the 15 factors compared between the two stocks. Remove Ads Get Jasper Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for JSPR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart JSPR vs. The Competition Export to ExcelMetricJasper TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$67.00M$3.03B$5.63B$7.83BDividend YieldN/A1.56%4.57%4.00%P/E Ratio-0.9428.9323.3318.68Price / SalesN/A429.70388.4691.04Price / CashN/A168.6838.1634.64Price / Book0.633.926.894.23Net Income-$64.46M-$71.95M$3.20B$247.15M7 Day Performance-14.40%-5.60%-3.02%-2.17%1 Month Performance-24.79%-11.96%1.63%-5.68%1 Year Performance-84.81%-28.47%9.74%-0.67% Jasper Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)JSPRJasper Therapeutics2.9932 of 5 stars$4.46-7.9%$62.50+1,301.3%-84.8%$67.00MN/A-0.9420Short Interest ↓Positive NewsATAIAtai Life Sciences3.2818 of 5 stars$1.57+8.3%$9.00+473.2%-25.4%$311.34M$308,000.00-1.9480TERNTerns Pharmaceuticals4.2832 of 5 stars$3.51+4.8%$18.30+421.4%-55.5%$298.14MN/A-2.9740PROKProKidney2.109 of 5 stars$1.02+6.2%$5.00+390.2%-44.5%$297.50M$76,000.00-1.853ANNXAnnexon2.2194 of 5 stars$2.70+12.5%$15.80+485.2%-68.6%$296.22MN/A-2.5760Gap UpGOSSGossamer Bio3.7618 of 5 stars$1.28-7.9%$9.20+618.8%-0.8%$290.84M$114.70M-4.00180Analyst RevisionCMPSCOMPASS Pathways3.6516 of 5 stars$3.11+0.3%$21.83+602.0%-64.7%$288.21MN/A-1.41120Analyst ForecastPositive NewsSEPNSepterna2.0609 of 5 stars$6.37+7.6%$34.00+433.8%N/A$282.85M$981,000.000.00N/AEarnings ReportUpcoming EarningsAnalyst ForecastNews CoverageGap DownCADLCandel Therapeutics2.661 of 5 stars$8.66+7.4%$21.00+142.5%+276.6%$281.24M$120,000.00-5.0160DSGNDesign Therapeutics1.9909 of 5 stars$4.93+6.0%$8.00+62.3%+4.5%$279.84MN/A-5.8040Positive NewsAVIRAtea Pharmaceuticals2.6346 of 5 stars$3.20-0.6%$6.88+115.0%-27.5%$273.68MN/A-1.5570 Remove Ads Related Companies and Tools Related Companies Atai Life Sciences Alternatives Terns Pharmaceuticals Alternatives ProKidney Alternatives Annexon Alternatives Gossamer Bio Alternatives COMPASS Pathways Alternatives Septerna Alternatives Candel Therapeutics Alternatives Design Therapeutics Alternatives Atea Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:JSPR) was last updated on 3/29/2025 by MarketBeat.com Staff From Our PartnersA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredJust Revealed: The chip company making AI look primitiveIn his just-released video presentation, this renowned market strategist — who's been called "one of the most ...InvestorPlace | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Jasper Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Jasper Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy JSPR Stock Free JSPR Stock Alerts